Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effektivitet och säkerhetsstudie av dovramilast hos personer med spetälska reaktion av typ 2

1 november 2026 uppdaterad av: Medicines Development for Global Health

En 12-veckors, öppen etikett, randomiserad, standard för vårdstyrd, dosavtalande säkerhet och effektivitetsstudie av dovramilast hos personer med måttlig till allvarlig akut eller återkommande spetälska reaktion av typ 2

Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

45

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Abomey-Calavi, Benin
        • Har inte rekryterat ännu
        • Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
      • Divo, Côte d’Ivoire
        • Har inte rekryterat ännu
        • Chr de Divo
      • Manila, Filippinerna
        • Rekrytering
        • Philippine General Hospital, University of the Philippines, Manila
        • Kontakt:
    • Washington
      • Seattle, Washington, Förenta staterna, 98104
        • Rekrytering
        • Harborview Medical Center, University of Washington
        • Kontakt:
          • Dr Jason Simmons, MD, PhD
          • Telefonnummer: 206-744-5463
          • E-post: jasonds@uw.edu
      • Yogyakarta, Indonesien
        • Rekrytering
        • Universitas Gadjah Mada
        • Kontakt:
      • Tôlanaro, Madagaskar
        • Rekrytering
        • Programme national lutte contre la lèpre
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Aged 18 years of age or older.

  2. Provision of written informed consent.

  3. Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.

  4. Leprosy type 2 reaction meeting the following criteria:

    • Either:

      i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).

    • Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).

    • An ENLIST score of at least 9.

  5. If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.

  6. If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.

Exclusion Criteria:

  1. Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been < 28 days.

  2. Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.

  3. Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).

  4. Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).

  5. Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.

  6. Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.

  7. Active systemic fungal infection requiring or undergoing treatment.

  8. Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.

  9. Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.

  10. Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.

  11. Pregnant women or breastfeeding mothers.

  12. Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.

  13. Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.

  14. Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.

  15. Current diagnosis of depression, and/or history of suicide ideation

  16. History of or presence of cardiac disease, including:

    • Clinically significant abnormal electrocardiogram
    • QTcF > 450 msec
  17. Receipt of a vaccination within 7 days of Baseline.

  18. Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.

  19. Body Mass Index < 15 kg/m^2 or > 35 kg/m^2.

  20. Unable to, or significant difficulty with, swallowing tablets/capsules.

  21. Anemia requiring transfusion.

  22. History of or current pancreatitis.

  23. Known or suspected cirrhosis of the liver.

  24. The following laboratory abnormalities:

    • White blood cells (WBC) < 2.5 x 10^9/ L.
    • Neutrophils (granulocytes) < 1.0 x 10^9/L.
    • Platelets < 80 x 10^9/L.
    • Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of reference range.
    • Albumin < 30 mg/dL.
    • Bilirubin > 2 mg/dL
    • Calculated creatinine clearance (Cockcroft Gault) < 50 milliliter (mL)/minute.
    • Lipase ≥ 1.6 times the upper limit
  25. Previous participation in this study

  26. Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments

  27. Enrolled in another leprosy type 2 reaction treatment study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dovramilast 100 mg

Dovramilast

Experimentell: Dovramilast 150 mg

Dovramilast

Aktiv komparator: Standard of care

Prednisolone (or thalidomide US sites only)

Standard of care

Standard of care (US only)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12
Tidsram: 12 weeks

The proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count of at least 75% from Baseline at Week 12 without the need for rescue.

Rescue is defined as:

  1. A change from dovramilast at any dose to standard of care or dose maintenance beyond taper time points defined in standard of care treatment guidelines (and specified in this protocol), or
  2. Standard of care dose increase, switching to or adding another leprosy type 2 reaction treatment
12 weeks
Incidence and severity of adverse events
Tidsram: 12 weeks

The incidence and severity of adverse events, changes in vital signs and blood dyscrasias

12 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Ändra från baslinjen Enkel (Erythema nodosum leprosum internationell studie) Svårighetsskala poäng
Tidsram: Vid varje tidspunkt efter baslinjen
Vid varje tidspunkt efter baslinjen
Förändringar i neuropati från baslinjen
Tidsram: 12 veckor
12 veckor
Andel personer som kräver räddningsmedicinering och tid till initiering av räddningsmedicin
Tidsram: 12 veckor
12 veckor
Total behandling för spetälskningstyp 2 -reaktion administrerad
Tidsram: 12 veckor
12 veckor
Resolution of fever to ≤ Grade 1
Tidsram: 12 weeks

Proportion of subjects with resolution of fever to ≤ Grade 1 among the subgroup of subjects with fever present at Baseline at Grade 2 or greater.

12 weeks
Skin lesion count changes
Tidsram: 12 weeks

• Change from Baseline in skin lesion count up to and including Week 12.

12 weeks
Change from Baseline of each of the following parameters when present at Baseline at Grade 2 or greater
Tidsram: from baseline to Week 12
  • Leprosy type 2 reaction lesions with respect to: number, inflammation, and extent
  • Neuritis
  • Pain:
  • Fever
  • Peripheral edema with respect to location and severity
  • Inflammation of joints and/or digits
  • Lymphadenopathy
from baseline to Week 12
Time to resolution
Tidsram: 12 weeks

For each individual leprosy type 2 reaction when present at least Grade 1 at Baseline

12 weeks
Recurrences
Tidsram: 48 weeks

Recurrence is defined as new signs and symptoms consistent with leprosy type 2 reaction. The number of Recurrence episodes requiring treatment.

48 weeks
Exposure metrics of dovramilast
Tidsram: 48 weeks

Area under the curve (AUC)

48 weeks
Exposure metrics of the dovramilast metabolite M15
Tidsram: 48 weeks

Area under the curve (AUC)

48 weeks
Skin lesion count changes
Tidsram: 12 weeks

• Proportion of Responders at each post-Baseline timepoint.

12 weeks
Skin lesion count changes
Tidsram: 12 weeks

Proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count from Baseline of 50%, 90% and 100% without Rescue at Week 12.

12 weeks
Exposure metrics of dovramilast
Tidsram: 48 weeks

Including AUC, Cmax, and Tmax.

48 weeks
Exposure metrics of dovramilast
Tidsram: 48 weeks

Cmax

48 weeks
Exposure metrics of dovramilast
Tidsram: 48 weeks

Tmax.

48 weeks

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Quantification of immunological markers in whole blood samples by central laboratory, blinded to patient identification, treatment arm, and study visit
Tidsram: 48 weeks

Concentration of inflammatory cytokines

48 weeks
Quantification of immunological markers in skin biopsies by central laboratory, blinded to patient identification, treatment arm, and study visit
Tidsram: 48 weeks

Leukocyte infiltration of skin lesions by histology

48 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 oktober 2026

Primärt slutförande (Beräknad)

1 januari 2027

Avslutad studie (Beräknad)

1 juli 2028

Studieregistreringsdatum

Först inskickad

7 augusti 2025

Först inskickad som uppfyllde QC-kriterierna

7 september 2025

Första postat (Faktisk)

15 september 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera